Circulating LTD4 in patients with hepatocellular carcinoma

Area of Science:

• Biochemistry
• Oncology
• Immunology

Background:

• Hepatocellular carcinoma (HCC) is an inflammation-related cancer.
• Leukotriene D4 (LTD4), a lipid mediator, is involved in inflammation and cancer.
• Previous studies indicated LTD4 overexpression in other cancers, but its role in HCC was unknown.

Purpose of the Study:

• To measure circulating LTD4 concentrations in HCC patients.
• To investigate the association of LTD4 with HCC tumor burden and inflammation markers.
• To explore the relationship between LTD4 and chronic hepatitis B (CHB) in HCC.

Main Methods:

• Quantification of circulating LTD4 levels in HCC patients and healthy controls.
• Correlation analysis of LTD4 levels with tumor markers (AFP) and inflammation factors (AST, γ-GT).
• Comparison of LTD4 levels between HCC patients with and without CHB.

Main Results:

• Significantly higher circulating LTD4 levels were observed in HCC patients compared to healthy subjects (p < 0.001).
• LTD4 levels did not correlate with tumor burden (AFP) or inflammation markers (AST, γ-GT).
• HCC patients with CHB showed significantly higher LTD4 levels than those with HCC alone (P < 0.05).

Conclusions:

• Circulating LTD4 levels are elevated in HCC.
• LTD4 may contribute to HCC pathogenesis, potentially as an inflammatory factor originating from CHB.
• Further research is needed to elucidate the precise role of LTD4 in HCC development.